Accompanying these findings is a call for refined treatment strategies that have potential to better outcomes among patients ...

TUESDAY, Nov. 26, 2024 (HealthDay News) -- Cisplatin is the go-to chemotherapy for people battling head-and-neck cancers, but ...

单克隆抗体西妥昔单抗虽然不如顺铂有效，但在这些患者中经常用作替代药物。然而，目前对这一人群的护理标准尚无共识。Durvalumab，一种免疫检查点抑制剂，已经显示出治疗多种癌症的希望，并被认为是比西妥昔单抗更安全、更有效的选择，根据Loren Mell医学 ...

Patients experienced similar safety and efficacy if they received first-line or later-line treatment for unresectable ...

In this randomized controlled trial, adjuvant therapy with durvalumab led to improved overall and progression-free survival ...

Head and neck cancers are the seventh most common type of cancer worldwide, according to the 2020 World Cancer Report.

AstraZeneca Pharma India has received regulatory approval to import and distribute Lynparza (Olaparib) tablets in 100mg and ...

Olaparib in combination with Durvalumab is indicated for the maintenance treatment of adult patients with advanced or ...

Discover the trials that have shown why Predictive biomarkers are expected to play a pivotal role in further enhancing ...

Bangalore: AstraZeneca Pharma India Limited has received permission to import for sale and distribution in Form CT-20 from ...

The Central Drugs Standard Control Organisation granted approval for the drug's use in combination with Durvalumab for the ...